Cogent Biosciences Inc
NASDAQ:COGT
Relative Value
The Relative Value of one
COGT
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 35.68 USD,
Cogent Biosciences Inc
is
hidden
.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
COGT Competitors Multiples
Cogent Biosciences Inc Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Cogent Biosciences Inc
NASDAQ:COGT
|
5.7B USD | 0 | -20.7 | -14.1 | -13.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
391.5B USD | 6.4 | 93.5 | 15.4 | 21.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
197.4B USD | 5.4 | 25.6 | 14.7 | 14.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
180.2B USD | 6.1 | 21.2 | 13.2 | 16.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.4B USD | 9.9 | 29.9 | 22.6 | 23.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80B USD | 5.6 | 17.8 | 13.2 | 15.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.4B AUD | 3.1 | 34.3 | 11.3 | 14.2 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
37.7B EUR | 10.7 | 34.5 | 37.3 | 38.1 |